Valerie D Nolt1, Alexandra Victoria Kibler2, G Lucy Wilkening3, Tanya J Fabian4,5. 1. University of Kentucky HealthCare, Lexington, KY, USA. 2. Penn State Milton S Hershey Medical Center, Pittsburgh, PA, USA. 3. University of the Incarnate Word Feik School of Pharmacy, 4301 Broadway, Box 99, San Antonio, TX, 78209, USA. wilkenin@uiwtx.edu. 4. University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA. 5. Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Second-generation antipsychotics (SGAs) are prescribed for a variety of indications and are strongly associated with adverse metabolic effects. Studies of pediatric outpatients have revealed several deficiencies in monitoring practices for adverse effects associated with SGAs. OBJECTIVE: Our objective was to characterize SGA prescribing and metabolic parameter monitoring (MPM) in an inpatient pediatric population. METHODS: Patients aged <18 years and discharged on SGA treatment between 1 November 2013 and 30 April 2014 from an inpatient psychiatric institution in Pittsburgh, PA, USA were included. Electronic medical records (EMRs) were reviewed for patient age and weight and for parameters used by the International Diabetes Federation (IDF) to define metabolic syndrome: waist circumference, fasting blood glucose, triglycerides, high-density lipoprotein, and blood pressure. The primary outcome was the percent of patients with completed MPM, defined as all parameters being available within the patient's EMR in any form, except estimates. Secondary outcomes included percent of patients with existing metabolic syndrome or obesity according to IDF criteria, average total daily dose of individual SGAs, and frequency of individual SGA utilization. Data were analyzed utilizing univariate descriptive statistics. RESULTS: A total of 243 patients met inclusion criteria and were included in the analysis. For the primary outcome, 13.2% (n = 32) of patients had completed MPM for all parameters. Blood pressure was the most frequently documented parameter (n = 241; 99.2%), whereas waist circumference was the least (n = 67; 28%). Risperidone was the most commonly prescribed SGA (n = 99; 41%; average daily dose 1.92 mg). CONCLUSIONS: Compared with outpatient studies, rates of documented MPM for certain parameters (i.e., fasting blood glucose, lipids) is higher for pediatric inpatients treated with SGAs. However, several monitoring deficiencies are still noted.
BACKGROUND: Second-generation antipsychotics (SGAs) are prescribed for a variety of indications and are strongly associated with adverse metabolic effects. Studies of pediatric outpatients have revealed several deficiencies in monitoring practices for adverse effects associated with SGAs. OBJECTIVE: Our objective was to characterize SGA prescribing and metabolic parameter monitoring (MPM) in an inpatient pediatric population. METHODS:Patients aged <18 years and discharged on SGA treatment between 1 November 2013 and 30 April 2014 from an inpatient psychiatric institution in Pittsburgh, PA, USA were included. Electronic medical records (EMRs) were reviewed for patient age and weight and for parameters used by the International Diabetes Federation (IDF) to define metabolic syndrome: waist circumference, fasting blood glucose, triglycerides, high-density lipoprotein, and blood pressure. The primary outcome was the percent of patients with completed MPM, defined as all parameters being available within the patient's EMR in any form, except estimates. Secondary outcomes included percent of patients with existing metabolic syndrome or obesity according to IDF criteria, average total daily dose of individual SGAs, and frequency of individual SGA utilization. Data were analyzed utilizing univariate descriptive statistics. RESULTS: A total of 243 patients met inclusion criteria and were included in the analysis. For the primary outcome, 13.2% (n = 32) of patients had completed MPM for all parameters. Blood pressure was the most frequently documented parameter (n = 241; 99.2%), whereas waist circumference was the least (n = 67; 28%). Risperidone was the most commonly prescribed SGA (n = 99; 41%; average daily dose 1.92 mg). CONCLUSIONS: Compared with outpatient studies, rates of documented MPM for certain parameters (i.e., fasting blood glucose, lipids) is higher for pediatric inpatients treated with SGAs. However, several monitoring deficiencies are still noted.
Authors: Elaine H Morrato; Ginger E Nicol; David Maahs; Benjamin G Druss; Daniel M Hartung; Robert J Valuck; Elizabeth Campagna; John W Newcomer Journal: Arch Pediatr Adolesc Med Date: 2010-04
Authors: Angie Mae Rodday; Susan K Parsons; Christoph U Correll; Adelaide S Robb; Bonnie T Zima; Tully S Saunders; Laurel K Leslie Journal: J Child Adolesc Psychopharmacol Date: 2014-03 Impact factor: 2.576
Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin Journal: Health Serv Res Date: 2012-09-04 Impact factor: 3.402
Authors: Mariken Dinnissen; Andrea Dietrich; Judith H van der Molen; Anne M Verhallen; Ynske Buiteveld; Suzanne Jongejan; Pieter W Troost; Jan K Buitelaar; Barbara J van den Hoofdakker; Pieter J Hoekstra Journal: J Clin Psychopharmacol Date: 2021 Jan/Feb 01 Impact factor: 3.118
Authors: Deborah Winders Davis; W David Lohr; Yana Feygin; Liza Creel; Kahir Jawad; V Faye Jones; P Gail Williams; Jennifer Le; Marie Trace; Natalie Pasquenza Journal: BMC Psychiatry Date: 2021-06-10 Impact factor: 3.630